Prognostic value of GLUT-1 expression in pancreatic cancer: results from 538 patients
Metrics: PDF 1290 views | HTML 3171 views | ?
Gaowa Sharen1,2,*, Yaojun Peng1,*, Haidong Cheng3,*, Yang Liu4, Yonghong Shi5, Jian Zhao1,6
1Cancer Center Key Lab, Chinese PLA General Hospital & Chinese PLA Medical School, Beijing 100853, P. R. China
2Molecular Pathology Laboratory, College of Basic Medicine, Inner Mongolia Medical University, Inner Mongolia 010059, P. R. China
3Department of General Surgery, The First Affiliated Hospital of Inner Mongolia Medical University, Inner Mongolia 010059, P. R. China
4Department of Endocrine, Chinese PLA 309 Hospital, Beijing 100071, P. R. China
5Department of Pathology, The Affiliated Hospital of Inner Mongolia Medical University, Inner Mongolia 010059, P. R. China
6International Joint Cancer Institute, The Second Military Medical University, Shanghai 200433, P. R. China
*These authors have contributed equally to this work
Yonghong Shi, email: [email protected]
Jian Zhao, email: [email protected]
Keywords: pancreatic cancer, biomarker, meta-analysis, clinical, epidemiology
Received: September 20, 2016 Accepted: January 07, 2017 Published: February 02, 2017
Objective: Previous studies have suggested a correlation between glucose transporter-1 (GLUT-1) expression and survival outcomes in pancreatic cancer, although the results were inconsistent. We subsequently carried out a meta-analysis, with the aim of comprehensively reevaluating the associations between GLUT-1 expression and overall survival (OS) and other clinical features of pancreatic cancer.
Results: Eight studies, with a total of 538 cases, were included in the final meta-analysis. The HR and 95% CI for OS were 1.79 and 1.19-2.7, respectively (p=0.005). GLUT-1 overexpression was associated with tumor size (>2 cm vs. ≤2 cm; OR=2.16, 95% CI=1.2-3.9, p=0.01) and lymph node metastasis (yes vs. no; OR=3.29, 95% CI=1.38-7.84, p=0.007). However, there was no significant association between GLUT-1 expression and histological grade, age, sex, TNM stage, or vascular invasion status. There was no evidence of significant publication bias in this meta-analysis.
Materials and Methods: Relevant databases were searched using predefined searching items until September 2016. The pooled hazard ratios (HR) with 95% confidence interval (CI) for OS and the pooled odds ratio (OR) with 95% CI for clinical factors were calculated.
Conclusions: High GLUT-1 expression predicted shorter OS in patients with pancreatic cancer. Moreover, GLUT-1 expression was associated with a tumor size of >2 cm and presence of lymph node metastasis.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.